RLMD - Relmada Therapeutics EPS beats by $0.06 May, 12 2021 04:27 PM Relmada Therapeutics Inc. Relmada Therapeutics (RLMD): Q1 GAAP EPS of -$1.34 beats by $0.06.Cash, cash equivalents, and short-term investments of $102.7M.Press Release For further details see: Relmada Therapeutics EPS beats by $0.06